Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Bortezomib rescue in refractory acute humoral rejection--report of a case.

Shapiro R, Basu A, Zeevi A, Lunz J, Mapara M, Randhawa P, Morgan C, Tan HP, Sharma V.

Clin Transpl. 2009:431-2. No abstract available.

PMID:
20524310
2.

Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?

Lee I, Constantinescu S, Gillespie A, Swami A, Birkenbach M, Leech S, Silva P, Karachristos A, Daller JA, Sifontis NM.

Clin Transpl. 2009:425-9. No abstract available.

PMID:
20524309
4.

Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series.

Lachmann N, Schütz M, Budde K, Schönemann C, Waiser J.

Clin Transpl. 2009:351-8.

PMID:
20527073
5.

Rescue therapy for early antibody mediated rejection with a proteasome inhibitor: a case report.

Manitpisitkul W, Wilson N, Cooper M, Gurk-Turner C, Hurley H, Rasetto F, KuKuruga D, Barth RN, Philosophe B.

Clin Transpl. 2009:461-3. No abstract available.

PMID:
20524315
6.

Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.

Al Meshari K.

Clin Transpl. 2009:385-6. No abstract available.

PMID:
20524302
7.

Use of bortezomib for prevention and treatment of rejection in sensitized patients.

Hartono C, Lubetzky M, Aull MJ, Saal S, Figueiro J, Kapur S, Dadhania D.

Clin Transpl. 2009:499-503.

PMID:
20524323
8.

Acute rejection in a highly sensitized lung transplant recipient with pre-formed donor-directed anti-HLA class II antibodies: role of bortezomib therapy.

Stuckey LJ, Kamoun M, Wadhwa A, Samaniego M, Bartos C, Berry J, Mahidhara R, Chang AC, Chan KM.

Clin Transpl. 2009:471-4. No abstract available.

PMID:
20524317
9.

Bortezomib for acute humoral rejection in two repeat transplant recipients.

Hardinger KL, Alford K, Murillo D.

Clin Transpl. 2009:479-83.

PMID:
20524319
10.

Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.

Walsh RC, Everly JJ, Brailey P, Rike AH, Arend LJ, Mogilishetty G, Govil A, Roy-Chaudhury P, Alloway RR, Woodle ES.

Transplantation. 2010 Feb 15;89(3):277-84. doi: 10.1097/TP.0b013e3181c6ff8d.

PMID:
20145517
11.

Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases.

Cooper JE, Wiseman AC, Chan L.

Clin Transpl. 2009:455-9. No abstract available.

PMID:
20524314
12.

Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.

Hamawi K, Heilman RL, Mazur MJ, Chakkera HA, Mulligan DC, Moss AA, Mekeel KL, Reddy KS.

Clin Transpl. 2009:407-14. No abstract available.

PMID:
20524306
13.

Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases.

Mai HL, Cesbron A, Brouard S, Blanchol G, Cantarovich D, Dantal J, Hourmant M, Lino M, Meurette A, Gosselin M, Abbadie O, Soulillou JP, Giral M.

Clin Transpl. 2009:361-8. No abstract available.

PMID:
20524299
14.

Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates.

Wahrmann M, Haidinger M, Körmöczi GF, Weichhart T, Säemann MD, Geyeregger R, Kikić Z, Prikoszovich T, Drach J, Böhmig GA.

Transplantation. 2010 Jun 15;89(11):1385-90. doi: 10.1097/TP.0b013e3181d9e1c0.

PMID:
20335829
15.

Abrogation of anti-HLA antibodies via proteasome inhibition.

Trivedi HL, Terasaki PI, Feroz A, Everly MJ, Vanikar AV, Shankar V, Trivedi VB, Kaneku H, Idica AK, Modi PR, Khemchandani SI, Dave SD.

Transplantation. 2009 May 27;87(10):1555-61. doi: 10.1097/TP.0b013e3181a4b91b.

PMID:
19461494
16.

The fate of anti-HLA antibody among renal transplantation recipients treated with bortezomib.

Lonze BE, Dagher NN, Simpkins CE, Singer AL, Segev DL, Zachary AA, Montgomery RA.

Clin Transpl. 2009:377-84.

PMID:
20524301
17.

The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation.

Flechner SM, Fatica R, Askar M, Stephany BR, Poggio E, Koo A, Banning S, Chiesa-Vottero A, Srinivas T.

Transplantation. 2010 Dec 27;90(12):1486-92. doi: 10.1097/TP.0b013e3181fdd9b0.

PMID:
21042239
18.

Use of bortezomib as adjunctive therapy for densensitization in combined heart and kidney transplantation--a case report.

Patel JK, Everly MJ, Kittleson M, Kobashigawa JA.

Clin Transpl. 2009:347-9. No abstract available.

PMID:
20524297
19.

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Tevar A, Woodle ES.

Transplantation. 2008 Dec 27;86(12):1754-61. doi: 10.1097/TP.0b013e318190af83.

PMID:
19104417
20.

Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.

Sureshkumar KK, Hussain SM, Marcus RJ, Ko TY, Khan AS, Tom K, Vivas CA, Parris G, Jasnosz KM, Thai NL.

Clin Nephrol. 2012 Mar;77(3):246-53. Review.

PMID:
22377258

Supplemental Content

Support Center